135 related articles for article (PubMed ID: 37941544)
1. Incidence and outcome of immune checkpoint-induced pneumonitis in oncology patients with history of pulmonary disease.
Allen E; Umoru G; Ajewole V; Bernicker E
Front Oncol; 2023; 13():1283360. PubMed ID: 37941544
[TBL] [Abstract][Full Text] [Related]
2. Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients.
Sun X; Song Z; Jiang H; Ma Y; Chen M
Clin Imaging; 2022 Jun; 86():31-37. PubMed ID: 35325631
[TBL] [Abstract][Full Text] [Related]
3. Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy.
Barrón F; Sánchez R; Arroyo-Hernández M; Blanco C; Zatarain-Barrón ZL; Catalán R; Ramos-Ramírez M; Cardona AF; Flores-Estrada D; Arrieta O
Front Oncol; 2020; 10():570233. PubMed ID: 33117699
[TBL] [Abstract][Full Text] [Related]
4. Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis.
Shu Y; Xu W; Su R; Ran P; Liu L; Zhang Z; Zhao J; Chao Z; Fu G
Front Immunol; 2023; 14():1251645. PubMed ID: 37799725
[TBL] [Abstract][Full Text] [Related]
5. Deep learning predicts immune checkpoint inhibitor-related pneumonitis from pretreatment computed tomography images.
Tan P; Huang W; Wang L; Deng G; Yuan Y; Qiu S; Ni D; Du S; Cheng J
Front Physiol; 2022; 13():978222. PubMed ID: 35957985
[TBL] [Abstract][Full Text] [Related]
6. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
[TBL] [Abstract][Full Text] [Related]
7. Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies.
Matsumoto K; Shiroyama T; Kuge T; Miyake K; Yamamoto Y; Yoneda M; Yamamoto M; Naito Y; Suga Y; Fukushima K; Koyama S; Iwahori K; Hirata H; Nagatomo I; Takeda Y; Kumanogoh A
Transl Lung Cancer Res; 2022 Sep; 11(9):1835-1846. PubMed ID: 36248332
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of combination therapy with glucocorticoids and pirfenidone for PD-1 inhibitor-related immune pneumonitis.
Li Y; Huang H; Ye X; Zeng B; Huang F; Chen L
Medicine (Baltimore); 2024 Apr; 103(16):e37808. PubMed ID: 38640289
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer.
Lu X; Wang J; Zhang T; Zhou Z; Deng L; Wang X; Wang W; Liu W; Tang W; Wang Z; Wang J; Jiang W; Bi N; Wang L
Front Immunol; 2022; 13():918787. PubMed ID: 35795657
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
Zhou P; Zhao X; Wang G
Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia.
Isobe K; Nakamura Y; Sakamoto S; Tomii K; Takimoto T; Miyazaki Y; Matsumoto M; Sugino K; Ichikado K; Moriguchi S; Yamaguchi K; Baba T; Ozasa H; Igata F; Anabuki K; Homma S; Date H; Suda T; Kishi K
ERJ Open Res; 2024 Mar; 10(2):. PubMed ID: 38444654
[TBL] [Abstract][Full Text] [Related]
12. The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis.
Ma K; Lu Y; Jiang S; Tang J; Li X; Zhang Y
Front Pharmacol; 2018; 9():1430. PubMed ID: 30618738
[No Abstract] [Full Text] [Related]
13. Comparison of Pneumonitis Rates and Severity in Patients With Lung Cancer Treated by Immunotherapy, Radiotherapy, and Immunoradiotherapy.
Aiad M; Fresco K; Prenatt Z; Tahir A; Ramos-Feliciano K; Stoltzfus J; Harmouch F; Wilson M
Cureus; 2022 Jun; 14(6):e25665. PubMed ID: 35677739
[TBL] [Abstract][Full Text] [Related]
14. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
[No Abstract] [Full Text] [Related]
15. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
[TBL] [Abstract][Full Text] [Related]
16. A Novel Workflow to Create a Checkpoint Inhibitor Pneumonitis Patient Registry.
Faucheux A; Olson E; Lantz J; Roberts N; Aggarwal V; Newman I; Ponnatapura J; Lycan T
Cureus; 2023 Feb; 15(2):e34683. PubMed ID: 36909081
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
18. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.
Beattie J; Rizvi H; Fuentes P; Luo J; Schoenfeld A; Lin IH; Postow M; Callahan M; Voss MH; Shah NJ; Betof Warner A; Chawla M; Hellmann MD
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33568350
[TBL] [Abstract][Full Text] [Related]
19. Safety of thoracic radiotherapy after PD-(L)1 inhibitor treatment in patients with lung cancer.
Chen Y; Liu X; Huang Z; Zhao K; Wang Y; Ren F; Yu J; Meng X
Cancer Med; 2021 Dec; 10(23):8518-8529. PubMed ID: 34664788
[TBL] [Abstract][Full Text] [Related]
20. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
